Connect Education Workshop Details
Help
Update on Chronic Myelogenous Leukemia (CML) from the 2009 American Society of Hematology (ASH) Annual Meeting
- Overview of CML
- New Treatment Approaches Reported at ASH
- How Clinical Trials Contribute to Treatment Options
- Communicating with Your Health Care Team
- Adherence: The Importance of Following Your Treatment Schedule
- Quality-of-Life Concerns
- Questions for Our Panel of Experts
Michael J. Mauro, MD Associate Professor, Center for Hematologic Malignancies, Oregon Cancer Institute, Oregon Health & Science University |
|
Neil Shah, MD, PhD Assistant Professor, Division of Hematology/Oncology, University of California San Francisco |
|
Elias Jabbour, MD Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center |
|
Richard Dickens, MSW Blood Cancers Program Coordinator, Project Coordinator, Mind/Body Program, CancerCare |
|
American Cancer Society, American Pain Foundation, American Society of Clinical Oncology, Association of Clinicians for the Underserved, Association of Oncology Social Work, Black Women's Health Imperative, Blood & Marrow Transplant Information Network, Cancer Patient Education Network, Education Network to Advance Cancer Clinical Trials, Gilda's Club Worldwide, Intercultural Cancer Council, Leukemia Research Foundation, Multinational Association of Supportive Care in Cancer, National Bone Marrow Transplant Link, National Center for Frontier Communities, National Coalition for Cancer Survivorship, National Family Caregivers Association, National Marrow Donor Program, Research Advocacy Network, Vital Options International & The Group Room, The Wellness Community
This program is made possible by a charitable contribution from Bristol-Myers Squibb.
December 10, 2009
